Peptides explained in plain language
Not medical advice
FDA-approvedCompounded · Rx

Sermorelin vs. tesamorelin: what’s the difference?

Both peptides prompt the body to release growth hormone, but their approval status and uses are very different.

Key takeaways

  • Sermorelin and tesamorelin both mimic the hormone that signals growth hormone release.
  • Tesamorelin (Egrifta) is FDA-approved for excess belly fat in adults with HIV.
  • Sermorelin's approved brand was discontinued for business reasons, and today it is compounded on prescription.
  • Neither is FDA-approved for anti-aging or general weight loss.

Sermorelin and tesamorelin often come up together in clinics that offer growth hormone therapies. They sound alike and work in a similar way. But they are not interchangeable, and their status with the FDA is quite different.

How they work

Both are man-made versions of growth hormone-releasing hormone, or GHRH. GHRH is the signal your brain sends to your pituitary gland to release growth hormone. Instead of giving growth hormone directly, these peptides prompt your body to make more of its own.

That is different from somatropin, which is growth hormone itself. Somatropin is a prescription biologic.

Here is how the two compare at a glance.

Sermorelin Tesamorelin
Approved product today None in the U.S. Yes, Egrifta
Past or current approved use Was approved as Geref for children with growth hormone deficiency, and as a diagnostic test Reduce excess belly fat in adults with HIV and lipodystrophy
How people get it now Prepared by compounding pharmacies on prescription Prescription brand-name drug
FDA review of the product you receive No, compounded drugs aren’t FDA-approved Yes, reviewed for safety, effectiveness and quality

Sermorelin’s history

Sermorelin was once sold under the brand name Geref. The maker discontinued it in 2008. The FDA later determined that it was not withdrawn for reasons of safety or effectiveness. Today, compounding pharmacies prepare sermorelin when a clinician writes a prescription.

Because compounded drugs are not FDA-approved, the FDA does not review each product for quality before you get it. The strength and purity depend on the pharmacy. Clinics may promote sermorelin for energy, body composition or aging, but those uses were never part of its approval.

Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

What to know about tesamorelin

Tesamorelin is sold as Egrifta. It is approved for one specific use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. The label says it is not meant for weight loss.

Its label lists real risks. These include a higher chance of glucose intolerance or diabetes, fluid retention, joint pain, injection-site reactions and allergic reactions. It also raises IGF-1, a hormone linked to growth, and the label advises monitoring it. Tesamorelin should not be used during pregnancy.

Because sermorelin works in a similar way, it is reasonable to ask your clinician whether similar risks could apply.

Questions to ask your clinician

  • What condition are you treating, and is this drug approved for it?
  • If it is compounded, which pharmacy makes it, and how is quality checked?
  • What tests will we do before and during treatment, such as blood sugar or IGF-1?
  • How will we know if it is working, and when would we stop?

The bottom line

Sermorelin and tesamorelin share a mechanism but little else. Tesamorelin is an approved drug for a narrow medical use. Sermorelin is a compounded product without a current approved version. Neither is approved to slow aging. A clinician and pharmacist can help you understand whether either fits your situation.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.